Agomab Therapeutics NV Adrs (AGMB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | |
| Assets | ||
| Current Assets | ||
| Cash & Cash Equivalents | 97,773 | 185,536 |
| Marketable Securities | 34,051 | N/A |
| Other current assets | 5,344 | 2,582 |
| TOTAL | $137,168 | $188,118 |
| Non-Current Assets | ||
| PPE Net | 569 | 670 |
| Investments And Advances | 12 | 13 |
| Intangibles | 32,496 | 31,080 |
| Other Non-Current Assets | 3,658 | 3,420 |
| TOTAL | $36,735 | $35,182 |
| Total Assets | $173,903 | $223,300 |
| Liabilities | ||
| Current Liabilities | ||
| Accounts payable and accrued liabilities | 11,615 | 8,713 |
| Other current liabilities | 7,384 | N/A |
| TOTAL | $21,032 | $9,875 |
| Non-Current Liabilities | ||
| Deferred Revenues | 1,751 | 867 |
| Other Non-Current Liabilities | 3,632 | 8,526 |
| TOTAL | $4,769 | $9,902 |
| Total Liabilities | $25,801 | $19,778 |
| Shareholders' Equity | ||
| Common Shares | 252,384 | 241,386 |
| Retained earnings | -205,591 | -128,966 |
| Other shareholders' equity | 14,606 | 8,176 |
| TOTAL | $148,103 | $203,522 |
| Total Liabilities And Equity | $173,903 | $223,300 |